Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: The Joslin 50-year medalist study

Diabetes Care

Volumn 34, Issue 4, 2011, Pages 968-974

  Sun, Jennifer K ^a,b   Keenan, Hillary A ^a,b   Cavallerano, Jerry D ^a,b   Asztalos, Bela F ^c   Schaefer, Ernst J ^c   Sell, David R ^d   Strauch, Christopher M ^d   Monnier, Vincent M ^d   Doria, Alessandro ^a   Aiello, Lloyd Paul ^a,b   King, George L ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBOXYETHYLLYSINE; HEMOGLOBIN A1C; LIPID; LYSINE DERIVATIVE; PENTOSIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PREVALENCE; UNITED STATES;

AGED; ARGININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; LYSINE; MALE; MIDDLE AGED;

EID: 79956213781     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1675     Document Type: Article

References (25)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
4. Cruickshanks KJ, Ritter LL, Klein R, Moss SE; The Wisconsin Epidemiologic Study of Diabetic Retinopathy. The association of microalbuminuria with diabetic retinopathy. Ophthalmology 1993;100:862-867
5. Chew EY, Klein ML, Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-1084
6. Sjølie AK, Stephenson J, Aldington S, et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe: the EURODIAB IDDM Complications Study. Ophthalmology 1997;104:252-260 (Pubitemid 27088100)
7. Gale EA. Glucose control in the UKPDS: what did we learn? Diabet Med 2008;25 (Suppl. 2):9-12 [Review. PubMed PMID: 18717972.]
8. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526
9. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community: the Blue Mountains Eye Study. Ophthalmology 1998;105:406-411 (Pubitemid 28125091)
10. Henricsson M, Nilsson A, Groop L, Heijl A, Janzon L. Prevalence of diabetic retinopathy in relation to age at onset of the diabetes, treatment, duration and glycemic control. Acta Ophthalmol Scand 1996;74:523-527 (Pubitemid 27042670)
11. Bain SC, Gill GV, Dyer PH, et al. Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med 2003;20:808-811 (Pubitemid 41701500)
12. Keenan HA, Costacou T, Sun JK, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year Medalist Study. Diabetes Care 2007;30:1995-1997 (Pubitemid 47219406)
13. Asztalos BF, Roheim PS, Milani RL, et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2670-2676
14. Sell DR, Strauch CM, Shen W, Monnier VM. 2-aminoadipic acid is a marker of protein carbonyl oxidation in the aging human skin: effects of diabetes, renal failure and sepsis. Biochem J 2007;404:269-277 (Pubitemid 46849598)
15. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992;41:153-159
16. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281-1289 (Pubitemid 24324972)
17. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007;9:233-245
18. Fan X, Monnier VM. Vitamin C-mediated Maillard reaction in the lens probed in a transgenic-mouse model. Ann N Y Acad Sci 2008;1126:194-200 (Pubitemid 351589326)
19. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005;54:3274-3281 (Pubitemid 43334385)
20. Brownlee M. The pathological implications of protein glycation. Clin Invest Med 1995;18:275-281 (Pubitemid 26004873)
21. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101 (Pubitemid 34146691)
22. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002;1:1-15 (Pubitemid 38340348)
23. Fosmark DS, Torjesen PA, Kilhovd BK, et al. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 2006;55:232-236 (Pubitemid 43098992)
24. Genuth S, Sun W, Cleary P, et al.; DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111
25. Amore A, Cirina P, Conti G, et al. Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 2004;19:53-60 (Pubitemid 38072615)